A rare case of de novo large cell neuroendocrine carcinoma of the prostate with long-term survival after cystoprostatectomy and androgen deprivation

Jimpei Miyakawa\textsuperscript{a,b}, Motofumi Suzuki\textsuperscript{h,*}, Kaori Endo\textsuperscript{c}, Yorito Nose\textsuperscript{d}, Toshikazu Sato\textsuperscript{e}, Yukiko Kishida\textsuperscript{f}, Koichi Tamura\textsuperscript{g}, Shoujiroh Morinaga\textsuperscript{g}, Haruki Kume\textsuperscript{b}, Yukio Homma\textsuperscript{h}

\textsuperscript{a} Department of Urology, Tokyo Teishin Hospital, Chiyoda-ku, Tokyo, Japan
\textsuperscript{b} Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
\textsuperscript{c} Department of Urology, Chugoku Tokushukai Hospital, Chigasaki-city, Kanagawa, Japan
\textsuperscript{d} Department of Urology, Chiba City General Hospital, Chiba-ku, Chiba, Japan
\textsuperscript{e} Department of Urology, Kanazawa University Hospital, Kanazawa, Japan
\textsuperscript{f} Department of Pathology, Tokyo Teishin Hospital, Chiyoda-ku, Tokyo, Japan
\textsuperscript{g} Department of Pathology, Tokai University Hospital, Minato-ku, Tokyo, Japan
\textsuperscript{h} Department of Urology, Japan Red Cross Medical Center, Shibuya-ku, Tokyo, Japan

Introduction

More than 95% of prostate cancers are adenocarcinoma, and neuroendocrine carcinomas (NECs) are very rare, representing less than 1% of prostate cancers. Among NECs of the prostate, small cell carcinoma (SmCC), carcinoids, and large cell neuroendocrine carcinoma (LCNEC) are rare histological types of prostate cancer with poor prognosis, and amongst them LCNEC is extremely rare. Fifteen cases have been reported to date. Ten cases occurred after long-term ADT, and three patients with de novo LCNEC whose NEOs are rare histological types of prostate cancer with poor prognosis, and amongst them LCNEC is extremely rare. Fifteen cases have been reported to date. Ten cases occurred after long-term ADT, and three patients with de novo LCNEC whose

Case report

An 87-year-old man visited our outpatient clinic with chief complaints of voiding difficulty and gross hematuria in August 2014. He previously underwent left nephroureterectomy for a renal pelvic tumor in July 2010 and transurethral resection of the bladder tumor (TURBT) for a urinary bladder tumor in June 2014. The pathological findings were low-grade pT1a urothelial carcinoma (UC) of the left renal pelvis and high-grade pTa UC of the urinary bladder, respectively.

The cystoscopy showed a sessile tumor on the neck of the urinary bladder, which we suspected as a muscle-invasive bladder cancer. The computed tomography and magnetic resonance imaging scans showed no evidence of metastases. The preoperative serum prostate-specific antigen (PSA) level was 3.3 ng/mL; however, the patient's prostate was found to be stony hard on a digital rectal examination. In October 2014, he underwent TURBT and the pathological findings indicated high-grade pT2 UC of the urinary bladder.

In November 2014, we performed radical cystoprostatectomy with urethrectomy, regional lymphadenectomy and right ureterocutaneostomy. The tumor was located mainly in the prostate and partially in the urinary bladder. The left side of the prostate firmly adhered to the pelvic wall, and it was difficult to peel off the site. Pathological findings were LCNEC with microscopic focus of acinar adenocarcinoma, Gleason score of 2 + 3, of the prostate. The LCNEC consisted of large tumor cells with high nucleus-to-cytoplasm (N/C) ratios, coarse nuclear chromatin, high mitotic rates, rosette structures, and fine granular cytoplasm (Fig. 1). The tumor replaced most of the prostate organ, confirming the origin as prostatic, invading into the urinary bladder. Immunohistochemical staining (IHS) of LCNEC and adenocarcinoma showed positivity for both PSA and androgen receptor (AR). Only the LCNEC showed positivity for CD56, chromogranin A, and synaptophysin. Two pathologists (KT and SM) independently diagnosed the patient with pT4 LCNEC and adenocarcinoma of the prostate with bladder invasion. A retrospective evaluation revealed that the muscle-invasive part in the previous TURBT specimen was LCNEC. Although there was no lymph node metastasis, the tumor had a positive surgical margin, perineural invasion, and extracapsular invasion; therefore, we started adjuvant ADT. Forty months after the surgery, the patient has survived with no evidence of tumor recurrence.

Discussion

NECs are rare histological types of prostate cancer with poor prognosis, and amongst them LCNEC is extremely rare. Fifteen cases have been reported to date. Ten cases occurred after long-term ADT, and five cases are de novo LCNEC.\textsuperscript{1-4} The clinical features of 6 case of de novo LCNEC including the present case are shown in Table 1. Azad et al. reported that ADT is likely effective for de novo LCNEC because such tumors remain androgen-dependency.\textsuperscript{7} Of five patients with de novo LCNEC whose...
prognoses were available in detail, three are alive without progression for more than 1 year. Although LCNEC generated after long-term ADT has a miserable prognosis,⁴ it is considered that de novo LCNEC has a relatively good prognosis.

IHS of AR was performed for two patients and both of them were positive for AR. Neuroendocrine cells, which commonly exist in prostate tissue including prostate cancer, and NEC cells are generally negative for AR and are considered androgen-independent.⁵ The expression of ARs on IHS indicates androgen-dependency in hormone naïve prostate cancer. AR-positivity of NEC also suggests androgen-dependency and efficacy of ADT. The long survival of the present AR-positive and surgical margin-positive LCNEC of the prostate after adjuvant ADT supports the hypothesis.

Table 1
Clinical Parameters and IHS features of LCNEC patients.

| Case   | Age (years) | PSA (ng/mL) | Treatment after diagnosis | Outcome          | Observation period | IHC of AR |
|--------|-------------|-------------|---------------------------|------------------|-------------------|-----------|
| No.1   | 69          | 4.3         | RP→Carboplatin + Etoposide| DOD              | Average 7 months after chemotherapy^a | N/A       |
| No.2   | 70          | 9.6         | ADT                       | Alive            | 15 months         | N/A       |
| No.3   | 71          | 170         | ADT                       | Alive            | 30 months         | N/A       |
| No.4   | 66          | 97          | N/A                       | N/A              | 13 months         | N/A       |
| No.5   | 48          | N/A         | Cisplatin + Etoposide + Paclitaxel + ADT→RP | DOD              | 45 months         | N/A       |
| Present case | 87          | 3.3         | Cystoprostatectomy→ADT     | Alive            |                  | +         |

Abbreviations
IHC, immunohistochemical staining; LCNEC, large cell neuroendocrine carcinoma; PSA, prostate specific antigen; AR, androgen receptor; RP, radical prostatectomy; DOD, died of disease; N/A, not applicable; ADT, androgen deprivation therapy.

^a The observation period of cases is described collectively with other 6 cases, not respectively.

^b There is no description of outcome after diagnosis.
Conclusion

LCNEC of the prostate is extremely rare. Most of cases present secondary to long-term ADT and the prognoses are generally very poor. This case suggests effectiveness of ADT for androgen-dependent LCNEC of the prostate. Androgen receptor-staining may be useful to predict efficacy of ADT on LCNEC of the prostate.

Conflicts of interest

None declared.

References

1. Azad AA, Jones EC, Chi KN. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy. Clin Genitourin Canc. 2014;12:151–153.
2. Acosta-Gonzalez G, Qin J, Wieczorek R, et al. De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. Am J Clin Exp Urol. 2014;2:337–342.
3. Okoye E, Choi EK, Divatia M, Miles BJ, Ayala AG, Ro JY. De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature. Int J Clin Exp Pathol. 2014;12:9061–9066.
4. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006;30:684–693.
5. Bonkhoff H, Stein U, Remmerber K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1993;423:291–294.